

Antagonism of 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane Stimulus with a Newly Identified 5-HT₂- versus 5-HT_{1C}-Selective Antagonist

Abd M. Ismaiel,[†] Joseph De Los Angeles,[†] Milt Teitler,[‡] Stacy Ingher,[‡] and Richard A. Glennon^{*†}

Department of Medicinal Chemistry, School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298-0540, and Department of Pharmacology, Albany Medical College, Albany, New York 12208

Received February 25, 1993

DOM [i.e., 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane] is a 5-HT_{1C/2} serotonin agonist that exerts stimulus control of behavior in animals. In order to determine if the discriminative stimulus effect of DOM is 5-HT_{1C}- or 5-HT₂-mediated, it would be informative to conduct tests of stimulus antagonism with a 5-HT_{1C}- or 5-HT₂-selective antagonist. To date, no such agents exist. Although the neuroleptic agent spiperone binds at D2 dopamine receptors and 5-HT_{1A} serotonin receptors, (a) it displays about a 1000-fold selectivity for 5-HT₂ versus 5-HT_{1C} sites and (b) it has been used as a "5-HT₂-selective" antagonist. Because spiperone is a behaviorally disruptive agent, it is not suitable for use in drug-discrimination studies. Using the spiperone molecule as a starting point, a limited structure-affinity investigation was conducted in order to identify a suitable antagonist with high affinity and selectivity for 5-HT₂ receptors, and yet an antagonist that might lack the disruptive actions of spiperone. Various modifications of the spiperone molecule were examined, but most resulted in decreased 5-HT₂ affinity or in loss of selectivity. One compound, 8-[3-(4-fluorophenoxy)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (**26**), was shown to bind at 5-HT₂ sites with high affinity ($K_i = 2$ nM) and >2,000-fold selectivity versus 5-HT_{1C} sites. In tests of stimulus antagonism using rats trained to discriminate 1 mg/kg of DOM from saline vehicle, **26** behaved as a potent antagonist ($ED_{50} = 0.003$ mg/kg) and lacked the disruptive effects associated with spiperone. As such, (a) it would appear that the DOM stimulus is primarily a 5-HT₂-mediated, and not 5-HT_{1C}-mediated, phenomenon, and (b) compound **26** may find application in other pharmacologic investigations where spiperone may not be a suitable antagonist.

Certain 4-substituted derivatives of 1-(2,5-dimethoxyphenyl)-2-aminopropane such as DOB, DOI, and DOM, where the 4-substituent is bromo, iodo, and methyl, respectively, are considered 5-HT₂ serotonin agonists.¹ We have previously used a drug-discrimination paradigm, employing rats trained to discriminate either DOB, DOI, or DOM from vehicle, to identify novel 5-HT₂ ligands and to investigate structure-activity relationships (reviewed²). We have demonstrated that the stimulus effects of these agents can be antagonized by 5-HT₂ antagonists and that stimulus generalization potency is significantly correlated with 5-HT₂ receptor affinity for a substantial series of agents that substitute for the DOM stimulus.² The discovery of 5-HT_{1C} receptors³ and the subsequent demonstration that they possess a significant sequence homology, and share a common second messenger system, with 5-HT₂ receptors led to the suggestion that 5-HT₂ and 5-HT_{1C} receptors be termed 5-HT_{2 α} and 5-HT_{2 β} receptors.⁴ Indeed, the aminopropane derivatives DOB, DOI, and DOM display little selectivity for one of these receptor populations versus the other and are more correctly referred to now as 5-HT_{1C/2} agonists.⁵ All of the "standard 5-HT₂ antagonists" (e.g. ketanserin) used to characterize the stimulus properties of these agents also appear to lack selectivity and bind nearly equally well at the two populations of sites.¹ Ketanserin, for example, binds at 5-HT₂ receptors only with 14-fold selectivity.⁶ In addition to the lack of agents selective for 5-HT₂ versus 5-HT_{1C} receptors has come the realization that many pharmacological and physiological effects once attributed to 5-HT₂ receptors may in fact involve a 5-HT_{1C} mech-

anism. Hence, there is a need to better define 5-HT_{1C} versus 5-HT₂ pharmacology.

The question now arises: is the DOM stimulus 5-HT₂- or 5-HT_{1C}-mediated? Despite the correlation between stimulus generalization and 5-HT₂ receptor affinity, a similar correlation exists between stimulus generalization and 5-HT_{1C} receptor affinity for the same series of agents.⁷ One way in which to clarify a role for one receptor type versus the other would be to use a selective agent to antagonize the DOM stimulus. To date, no 5-HT_{1C}-selective nor 5-HT₂-selective antagonists exist.⁸ One agent that has found some application as a 5-HT₂-selective antagonist is the neuroleptic spiperone (**1**); spiperone is generally considered to bind at 5-HT₂ versus 5-HT_{1C} receptors with about 500-1000-fold selectivity.¹ However, this agent also binds at another population of serotonin receptors (5-HT_{1A}), and binds at D2 dopamine receptors with an affinity ($K_i = 0.2$ nM) at least comparable to, if not higher than, its affinity for 5-HT₂ sites. Nevertheless, because the DOM stimulus does not appear to involve either a 5-HT_{1A} serotonin or D2 dopamine mechanism,² a demonstration of stimulus antagonism by low doses of spiperone would provide evidence that the DOM stimulus is likely 5-HT₂-mediated, whereas lack of antagonism (or antagonism only at very high doses of spiperone) would suggest involvement of a 5-HT_{1C} mechanism. Consequently, tests of DOM-stimulus antagonism with spiperone were conducted; unfortunately, these studies were inconclusive in that low doses of spiperone administered in combination with DOM resulted in severe behavioral disruption that prevented the animals from responding.²

Spiperone was instrumental in originally defining and differentiating the 5-HT₁ and 5-HT₂ families of receptors (reviewed¹) and may be viewed as the first known (albeit

[†] Virginia Commonwealth University.

[‡] Albany Medical College.

Table I. Physicochemical Data for Spiperone Analogues

	method ^a	% yield	RS ^b	mp, °C	empirical formula ^c
3	A	72	AE	199–201 ^d	
5	A	93	A	168–171	C ₉ H ₁₂ FNO·HCl
6	B ^e	42	AE	119–121	C ₁₁ H ₁₆ FNO·HCl
7	C	61	CA	133–135	C ₁₂ H ₁₆ FNO·HCl
8	B	48	AE	175–177 ^f	
9	B	35	HA	202–204	C ₂₁ H ₂₅ FN ₂ O·C ₂ H ₂ O ₄ ^{g,h}
10	B	6	A	171–173	C ₂₂ H ₂₆ FNO·HCl
12	B	37	AE	219–221	C ₂₂ H ₂₅ FN ₂ O ₂ ·C ₂ H ₂ O ₄ ^{h,i}
13	B	60	HA	175–177	C ₂₀ H ₂₅ FN ₂ O·C ₂ H ₂ O ₄
14	D	38	AE	145–147	C ₂₁ H ₂₇ FN ₂ O·C ₂ H ₂ O ₄
15	E	53	AE	195–197	C ₂₁ H ₂₅ FN ₂ O ₂ ·C ₄ H ₄ O ₄ ^j
16	B	36	A	168–170	C ₂₁ H ₂₅ FN ₂ O ₂ ·C ₂ H ₂ O ₄
17			AE	187–189 ^k	
18	F	17	A	204–207	C ₂₃ H ₂₆ FN ₃ O·HCl
19	F ^l	50	N	188–191	C ₂₃ H ₂₆ N ₃ O·C ₄ H ₄ O ₄ ^m
20	F ⁿ	21	AE	194–196 ^o	C ₂₂ H ₂₇ N ₃ O·C ₄ H ₄ O ₄
21	F ⁿ	44	AE	225–227 ^p	C ₂₁ H ₂₅ N ₃ O·C ₄ H ₄ O ₄
22	F ^r	30	AE	228–231 ^q	C ₂₂ H ₂₇ N ₃ O ₂ ·HCl
23	F ^r	37	A	207–209 ^r	C ₂₃ H ₂₆ N ₃ O ₂ ·HCl
24	F ^r	60	A	217–219 ^t	C ₂₃ H ₂₆ N ₃ O ₃ ·HCl
25	F ^r	50	AE	273–275	C ₂₂ H ₂₆ N ₄ O ₄ ·HCl
26	F ^r	60	MH	171–174 ^u	


^a See Experimental Section for representative methods. ^b Recrystallization solvents: absolute EtOH (A), anhydrous Et₂O (E), methanol (M), H₂O (H), MeCN (N), EtOAc (C). ^c Microanalytical (C, H, N) data within 0.4% of the theoretical values. ^d Literature⁹ mp 202–203 °C. ^e Reaction time of 18 h using MeCN as solvent. ^f Literature¹⁰ mp 177–178 °C. ^g Hydrogen oxalate salt. ^h Crystallized with 0.25 mol of H₂O. ⁱ Previously reported as free base, but no melting point reported.¹¹ ^j Maleate salt. ^k Prepared by literature method.¹² ^l Reaction time of 24 h using ethylene glycol dimethyl ether as solvent. ^m Crystallized with 0.5 mol of H₂O. ⁿ Reactants were fused together at 95–100 °C for 2 h. ^o Previously reported only as free base; free base mp 198–200 °C (lit¹³ mp 199–200 °C). ^p Previously reported only as free base; free base mp 171–172 °C (lit¹³ mp 170–172 °C). ^q Previously reported only as free base; free base mp 154–156 °C (lit¹³ mp 154–156 °C). ^r Reaction time 3 h using dioxane as solvent and K₂CO₃. ^s Previously reported only as free base; free base mp 169–171 °C (lit¹⁴ mp 85–112 (sic) °C). ^t Previously reported only as free base; free base mp 167–168 °C (lit¹⁴ mp 164–165.5 °C). ^u Literature¹⁴ free base mp 173–174 °C.

nonselective) 5-HT₂ ligand. Spiperone is also the only agent that has found any significant application as a 5-HT₂- versus 5-HT_{1C}-selective antagonist. And yet, essentially nothing has been reported about its 5-HT₂ (or 5-HT_{1C}) structure–affinity relationships. In an attempt to identify a novel ligand with 5-HT₂ versus 5-HT_{1C} selectivity at least comparable to that of spiperone, and yet an agent that might not disrupt animals in drug discrimination studies, we undertook a limited structure–affinity investigation of spiperone. 5-HT₂ and 5-HT_{1C} binding data were obtained and, because spiperone binds at 5-HT_{1A} receptors, 5-HT_{1A} binding data were also acquired. Our intent was not to exhaustively investigate structure–affinity relationships nor to develop an agent specific for 5-HT₂ receptors. Rather, we were interested in obtaining a 5-HT₂- versus 5-HT_{1C}-selective agent that would be useful in our drug-discrimination studies.

Chemistry

Most of the compounds (Table I) were prepared by simple alkylation procedures. For example, 4-chloro-1-(4-fluorophenyl)-1-butanone (27) or 1-chloro-3-(4-fluorophenoxy)propane (28) was aminated by reaction with potassium phthalimide followed by hydrazinolysis to afford the primary amines 3 and 5 (method A). The carbonyl group of 3 was protected as a ketal, followed by Eschweiler–Clarke alkylation and subsequent deprotection, to give

Scheme I^a



^a (a) 28/K₂CO₃/KI/dioxane; (b) 30% HOAc/HCl; (c) NaCNBH₄/NH₄Ac/MeOH; (d) PhC(O)Cl/NEt₃/CHCl₃.

Table II. Radioligand Binding Data for Some Spiperone-Related Compounds


R	R'	X	K _i , ^a nM			ratio ^b	
			5-HT _{1A}	5-HT _{1C}	5-HT ₂		
3	H	H	C=O	>100000	>100000	>100000	
5	H	H	O	ND ^c	>10000	1400(95)	>5
6	Me	Me	O	ND	>10000	295 (45)	>30
7	Me	Me	C=O	ND	3300 (285)	80 (10)	40
8	H	H	C=O	>10000	>10000	140 (10)	>70
9	NHPh	H	C=O	250 (12)	2300 (135)	34 (2)	65
10	CH ₂ Ph	H	C=O	180 (14)	1650 (300)	50 (14)	35
11	C(O)C ₆ H ₄ (4-F)	H	C=O	305 (68)	345 ^d	4 ^d	85
12	NHC(O)Ph	H	C=O	ND	>10000	70 (10)	>140
13	NHPh	H	O	120 (2)	3600 (270)	88 (12)	40
14	N(CH ₃)Ph	H	O	110 (15)	2870 (15)	32 (5)	90
15	NHC(O)Ph	H	O	4000 (50)	>10000	70 (2)	>140
16	C(O)NHPh	H	O	ND	>10000	95 (37)	>100
17	C(O)C ₆ H ₄ (4-F)	H	O	285 (45)	335 (35)	8 (2)	40

^a K_i values are followed by SEM; SEM not determined where the K_i > 10000 nM. ^b 5-HT₂ selectivity ratio (i.e., 5-HT_{1C}K_i + 5-HT₂K_i). ^c ND = not determined. ^d 5-HT₂ and 5-HT_{1C} binding data previously reported.⁶

the *N,N*-dimethyl derivative 7 (method C). Other substituted amines were prepared by reaction of 27 (*viz*: 8, 9, 10, 12) or 28 (*viz*: 6, 13, 16) either with *N,N*-dimethylamine (i.e., 6) or with the appropriately substituted piperidine derivative (method B). See Table I for physicochemical data.

Reductive alkylation of 13 with formaldehyde under catalytic conditions afforded 14 (method D). Compound 15 was prepared from the ketal-protected 4-piperidone 29 (Scheme I). Alkylation of 29 with 28, followed by deprotection, provided 31. Reductive amination of 31 with NaCNBH₄ and acylation of the resulting amine 32 with benzoyl chloride gave 15 (method E).

The triazaspirodecanone derivatives shown in Table III were prepared by alkylation of 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (2) with the appropriate alkyl bromide

Table III. Radioligand Binding Data for Triazaspirodecanone Derivatives

R	K_i^a , nM			ratio ^b
	5-HT _{1A}	5-HT _{1C}	5-HT ₂	
2 H	>10000	>10000	>10000	
1 (CH ₂) ₃ C(O)C ₆ H ₄ (4-F)	49(10)	1000(100)	1(0.5)	1000
18 (CH ₂) ₃ CH ₂ C ₆ H ₄ (4-F)	110(20)	3200(285)	5(0.5)	650
19 (CH ₂) ₄ Ph	85(2)	>10000	30(15)	>300
20 (CH ₂) ₃ Ph	105(5)	>10000	230(45)	>30
21 (CH ₂) ₂ Ph	1025(130)	6000(900)	570(140)	10
22 (CH ₂) ₃ OPh	75(1)	>10000	5(0.1)	>2000
23 (CH ₂) ₄ OPh	30(3)	>10000	325(30)	>30
24 (CH ₂) ₃ OC ₆ H ₄ (4-OMe)	445(30)	>10000	1000(100)	>10
25 (CH ₂) ₃ OC ₆ H ₄ (4-NO ₂)	1160(20)	>10000	600(160)	>10
26 (CH ₂) ₃ OC ₆ H ₄ (4-F)	50(2)	4300(770)	2(0.2)	2100


^a K_i values are followed by SEM; SEM not determined where the $K_i > 10000$ nM. ^b 5-HT₂ selectivity (i.e., 5-HT_{1C} K_i ÷ 5-HT₂ K_i).

(i.e., 19, 23), chloride (i.e., 22, 26), or tosylate (i.e., 18, 20, 21, 24, 25) (method F).

Results and Discussion

In the present study, spiperone (1; 5-HT₂ K_i = 1 nM) was found to bind with a 1000-fold selectivity for 5-HT₂ versus 5-HT_{1C} receptors (Table III). Our first goal was to identify how, and to what extent, each end of the spiperone (1) molecule contributes to 5-HT_{1C} and 5-HT₂ affinity and selectivity.

Benzoylalkylamine-Related Compounds. The triazaspirodecanone portion of spiperone (i.e., 2) binds with low affinity ($K_i > 10\ 000$ nM) both at 5-HT_{1C} and 5-HT₂ sites (Table III) leading us to believe that the fluorobenzoyl portion may be the more important for binding. Surprisingly, the primary amine 3 was also without affinity for these sites (Table II). We surmised that under the conditions of the binding assay, or upon dissolution in buffer prior to the assay, 3 might undergo internal Schiff base formation to give a cyclic product. Indeed, the ¹H-NMR spectrum of a solution of 3 in D₂O revealed the appearance of new peaks within a matter of hours. When examined at 72 h, these peaks were clearly resolved and suggested the possibility of the formation of imine 4. This



was subsequently confirmed by independent synthesis of 4 and a comparison of spectral data. Consequently, we prepared ether 5, which cannot undergo cyclization, and found that it binds, albeit with rather modest affinity, at 5-HT₂ sites (K_i = 1400 nM). The corresponding *N,N*-dimethylamino ether 6 (K_i = 295 nM) was found to bind with a several-fold improvement in 5-HT₂ affinity. Because the structure of interest was an aminopropiophenone (and not the corresponding ether) we prepared and examined the *N,N*-dimethyl analogue of 3 (i.e., 7) with the expectation that it would not as readily undergo cyclization. Compound 7 was found to bind at 5-HT₂ sites with respectable affinity (K_i = 80 nM) but only with a modest 40-fold selectivity.

It would appear then that the fluorobenzoyl portion of spiperone (e.g. 7) is important for binding, but that it does not bind with the selectivity of spiperone (1) itself. Evidently, it is a portion of the spiperone molecule that has been excised that is responsible for high affinity and selectivity. Consequently, portions of the spiperone molecule were reintroduced in a stepwise manner. The terminal amine substituent of 7 was elaborated to a piperidine moiety (i.e., spiperone minus all but the spiro atom of the phenylimidazolinone ring); this compound, 8 (K_i = 140 nM), results in retention of 5-HT₂ affinity and in a slight improvement in selectivity. The anilino function of spiperone was incorporated into 8 (i.e., 9) with further improvement in 5-HT₂ affinity (K_i = 34 nM) but with little effect on selectivity (65-fold selectivity). Replacement of the anilino nitrogen atom by a methylene group (i.e., 10) had little overall effect.

Examining a series of ketanserin analogues, we previously reported that 4-fluorobenzoylpiperidines bind at 5-HT₂ sites with high affinity; for example, 11 binds with a K_i value of 4 nM.⁶ Incorporation of this carbonyl moiety into anilino analogue 9 had little effect on affinity (12; K_i = 70 nM) but resulted in an agent that is essentially inactive at 5-HT_{1C} sites (i.e., in a >140-fold selectivity for 5-HT₂ versus 5-HT_{1C} receptors). This is further evidence that the amine substituents influence affinity and selectivity.

Early work on this project showed that the butyrophe none carbonyl group could be replaced by an ether oxygen atom. Compound 13 is the ether counterpart of 9; 14 is the *N*-methyl derivative of 13. Both compounds retain the 5-HT₂ affinity and selectivity of 9. The ether counterpart of amide 12 (i.e., 15), and its reverse amide 16, both behaved like 12. In each of these instances however, 5-HT₂ affinity is still 30–100 times less than that of spiperone. To complete the series, we prepared and examined the ether analogue of the higher affinity 11 (i.e., 17); once again, replacement of the carbonyl group by an ether oxygen atom had a negligible effect. Although 17 binds at 5-HT₂ sites with high affinity (K_i = 8 nM), it displayed only 40-fold selectivity over 5-HT_{1C} affinity.

Triazaspirodecanones. Because the highest affinity and most selective compound (i.e., spiperone) is associated with an intact azaspirodecanone ring, and because none of the structurally simpler analogues rivalled its affinity or selectivity, additional triazaspirodecanone derivatives were examined (Table III). Compound 18 (5-HT₂ K_i = 5 nM) is simply spiperone minus the alkyl-chain carbonyl oxygen; it retained high (>600-fold) selectivity for 5-HT₂ receptors. Removal of the fluoro group (19; K_i = 30 nM) somewhat decreased 5-HT₂ affinity but still resulted in a fairly (>300-fold) selective compound. Contraction of the 4-membered alkyl chain of 19 to a *n*-propyl (20; K_i = 230 nM) or ethyl group (21; K_i = 570 nM) decreased 5-HT₂ affinity; in the case of 21, selectivity was also reduced (Table III).


With the realization that a carbonyl group is not required for 5-HT₂ binding (e.g. see 19), and as suggested by studies with the ether derivatives (e.g. compare 12 with 15), we prepared and examined 22. Compound 22 binds at 5-HT₂ sites with high affinity (K_i = 5 nM) and >2000-fold selectivity. Homologation of the alkyl chain (i.e., 23), and incorporation of a *p*-methoxy (i.e., 24) or nitro group (i.e., 25), reduced 5-HT₂ affinity (Table III). However, incorporation of a *p*-fluoro group resulted in a slight enhance-

ment of 5-HT₂ affinity (26; 5-HT₂ K_i = 2 nM) with retention of >2000-fold 5-HT₂ versus 5-HT_{1C} selectivity.

Compound 26 (AMI-193) binds at 5-HT₂ sites with an affinity comparable to that of spiperone (1) and, by virtue of its lower affinity for 5-HT_{1C} sites (26; 5-HT_{1C} K_i = 4300 nM), displays about twice spiperone's 5-HT₂ versus 5-HT_{1C} selectivity. Compound 26 retains affinity for 5-HT_{1A} sites (K_i = 50 nM) and also binds at dopamine D2 sites (K_i = 3 ± 1 nM), but possesses low affinity for dopamine D1 sites (K_i = 2530 ± 50 nM). Overall, this compound is quite spiperone-like in its binding profile except that it binds with about 10-fold lower affinity than spiperone (K_i = 0.2 nM) at D2 sites. As such, this compound was a likely candidate for examination in drug-discrimination studies.

5-HT_{1C} Binding. Nearly all of the compounds were found to bind at 5-HT_{1C} sites with relatively low affinity. Indeed, only two compounds (11 and 17) displayed K_i values of <1000 nM. Consequently, it is difficult to comment on 5-HT_{1C} structure-affinity relationships for these compounds.

5-HT_{1A} Binding. Most of the compounds displayed modest affinity for 5-HT_{1A} serotonin receptors. General structure-affinity requirements for 5-HT_{1A} binding have been thoroughly investigated (reviewed^{1,15}) and the present work adds relatively little new insight. That is, 1-arylpiperazines are known to bind with high affinity at 5-HT_{1A} sites when they bear at the piperazine 4-position an alkyl (or alkoxy) group of two to five atoms separating the amine from an aryl substituent; replacement of the 1-position nitrogen atom by a carbon atom decreases 5-HT_{1A} affinity by several fold.¹⁵ Thus, most of the present compounds (e.g. 9–17) would be expected to bind only with modest affinity, and 8 (lacking a piperidine 4-position substituent) would be predicted to be inactive. On the other hand, essentially nothing is known about the 5-HT_{1A} affinity of triazaspirodecanone analogues. Evidently, this moiety is tolerated by 5-HT_{1A} receptors; however, to put this in proper perspective, 1-phenyl-4-[4-phenylbutyl]piperazine (35) binds with a K_i value of 1 nM¹⁶ compared to the corresponding triazaspirodecanone 19 (5-HT_{1A} K_i = 85 nM).



35

Drug-Discrimination Studies. Five rats were trained to discriminate 1.0 mg/kg of the 5-HT_{2/1C} agonist DOM from saline vehicle such that they made >90% of their responses on the drug-appropriate lever 15 min after administration of the training dose of the training drug, and <20% of their responses on the same lever after administration of saline. Tests of stimulus antagonism were conducted with 26 much in the same way we have previously examined spiperone.² The animals were administered 26 and, 45 min later, we administered 1.0 mg/kg of DOM. Each animal served as its own control. As shown in Figure 1, administration of 26 in combination with DOM resulted in antagonism of DOM-appropriate responding in a dose-related manner. Response rates at 0.04 mg/kg of 26 (11.6 ± 2.5 responses/min) were not different from response rates after the administration of 1.0 mg/kg of DOM in the absence of antagonist (11.9 ± 2.1




Figure 1. Antagonist effect of doses of 26 administered in combination with 1.0 mg/kg of DOM. The number of animals responding/the number treated, and the response rates (responses/min ± SEM), are given for each dose of 26: 0 (5/5; 11.9 ± 2.1), 0.001 (7/7; 18.2 ± 4.0), 0.005 (4/5; 13.2 ± 2.6), 0.02 (5/5; 10.6 ± 3.5), 0.04 (4/5; 11.6 ± 2.5). Administered alone, saline elicited 18% drug-appropriate response (5/5, 11.2 ± 2.2 responses/min). At the 0.001 mg/kg dose of 26, two of the animals were inadvertently tested twice. The ED₅₀ dose calculated for 26 is 0.003 mg/kg (95% CL, 0.002–0.06 mg/kg).

responses/min). Administration of 0.04 mg/kg of 26 in the absence of DOM (60 min prior to testing) resulted in less than 20% drug-appropriate responding (results not shown).

Unlike spiperone (1), which results in disruption of the animals' behavior when administered in combination with DOM,² 26 is capable of antagonizing the DOM stimulus. That is, at the doses necessary for stimulus antagonism, 26 appears to lack the behaviorally disruptive effects of spiperone. Not only does 26 display a >2000-fold selectivity for 5-HT₂ versus 5-HT_{1C} sites but the doses required for stimulus antagonism are also quite low (ED₅₀ = 0.003 mg/kg). Thus, although a contributory role for 5-HT_{1C} receptors cannot be conclusively ruled out, the present results convincingly argue that the DOM stimulus involves a 5-HT₂ mechanism.¹⁷

An alternative, although less likely, explanation for the present results is that DOM produces a compound stimulus (i.e., the DOM stimulus may involve both a 5-HT₂ and a 5-HT_{1C} mechanism), and that interference with either one of the two components could result in an apparent antagonism. This would seem unlikely in the present situation because training animals to recognize a compound stimulus (in the few instances where this has been recognized) typically requires an extended period of time, and unusually long training periods are not required to train rats to discriminate DOM from vehicle.² However, the only way to provide support for this possibility would be to demonstrate that 5-HT_{1C} antagonists (of which none currently exist) are equally effective in antagonizing the DOM stimulus.

DOM, in addition to being a 5-HT_{2/1C} agonist, is also a potent prototypical hallucinogen (see refs 2 and 7 and literature cited therein). In fact, although the exact mechanism of action of classical hallucinogens is unknown at this time, it has been proposed that such agents produce their hallucinogenic effects by virtue of being 5-HT₂ and/or 5-HT_{1C} agonists (reviewed⁷). Although the primary stimulus effect of DOM in animals is likely 5-HT₂-

mediated (this investigation), it still remains to be seen whether a 5-HT₂ or 5-HT_{1C} mechanism is more important for human hallucinogenic activity.

Summary. Spiperone (1) binds at 5-HT₂ receptors, relative to 5-HT_{1C} receptors, with high affinity and with 1000-fold selectivity. Due to its disruptive effects on animal behavior, spiperone is unsuitable for use in drug-discrimination studies. A limited structure-affinity study was undertaken to identify a spiperone substitute with comparable 5-HT_{2/1C} binding characteristics that might be useful in animal studies. Opening of the triazaspirodecanone ring (e.g. 9) resulted in a dramatic decrease in selectivity but in retention of modest 5-HT₂ affinity. Optimal 5-HT₂ affinity and selectivity seem to be associated with an intact triazaspirodecanone ring. Replacement of the carbonyl group of spiperone (1) with a methylene group (i.e., 18), and subsequent shortening of the alkyl chain (i.e., 19–21), decreased 5-HT₂ affinity and selectivity. However, replacement of the carbonyl group of spiperone (1) with an ether oxygen atom (i.e., 26) resulted in retention of spiperone's 5-HT₂ affinity and selectivity. Unlike spiperone, compound 26 (at least at the doses employed) (a) lacked the behaviorally disruptive effects of spiperone and (b) was found to be a potent antagonist of the DOM stimulus in rats. The present study suggests, due to the 5-HT₂ versus 5-HT_{1C} selectivity and behavioral potency of 26, that the stimulus effects of DOM are likely mediated primarily by a 5-HT₂, and not a 5-HT_{1C}, mechanism.

Experimental Section

Synthesis. Melting points were determined using a Thomas-Hoover capillary melting point apparatus and are uncorrected. Infrared spectra were recorded on a Nicolet 5ZDX FT-IR and proton magnetic resonance (NMR) spectra on a JEOL FX90Q FT-NMR spectrometer at 89.55 MHz. ¹³C-NMR spectra were obtained using a GE QE-300 at 300.64 MHz. All spectral data are consistent with assigned structures. Elemental analyses were performed by Atlantic Microlab Inc. (Norcross, GA) and values are within 0.4% of the theoretical values. Unless otherwise stated, salts were prepared by the following general procedure: (a) for maleates and oxalates, by the dropwise addition of a molar equivalent solution of maleic acid or oxalic acid in anhydrous Et₂O to a solution of the amine in anhydrous Et₂O or a mixture of absolute EtOH and anhydrous Et₂O, (b) for hydrochlorides, by the dropwise addition, until cessation of salt formation, of a saturated solution of HCl in anhydrous Et₂O to a solution of the amine in anhydrous Et₂O or absolute EtOH/Et₂O. Flash chromatography was performed on silica gel (Merck, grade 60, 230–400 mesh, 60 Å) using 9:1 CHCl₃/MeOH as eluent. MeCN was dried by distillation, THF was dried by distillation from LiAlH₄, and CHCl₃ was dried by distillation from P₂O₅; all solvents (except for Et₂O) were stored over 3- or 4-Å molecular sieves. All starting materials were purchased either from Aldrich Chemicals or from Janssen Chimica.

2-(4-Fluorophenyl)-Δ¹-pyrrolidine (4). A solution of 2-(4-fluorophenyl)-2-(3-aminopropyl)-1,3-dioxolane (34; 0.5 g, 2.26 mmol) in 30% aqueous HOAc was allowed to stir at room temperature for 6 h. Solvent was removed under reduced pressure. The oily residue was dissolved in Et₂O (75 mL); the solution was washed with saturated NaHCO₃ solution (25 mL) and then H₂O (25 mL), dried (Na₂SO₄), and evaporated to give an oil that crystallized to give 0.22 g (59%) of a yellow-orange solid upon standing: mp 37–39 °C (lit.²⁰ mp 38–39 °C); ¹H NMR (CDCl₃) δ 2.15 (m, 2H, CH₂), 2.95 (t, 2H, CH₂C=N), 4.05 (t, 2H, CH₂N), 7.1 (m, 2H, ArH), 7.85 (m, 2H, ArH); IR (KBr) 1621 (C=N) cm⁻¹.

3-(4-Fluorophenoxy)propylamine Hydrochloride (5). **Method A.** A mixture of potassium phthalimide (2.4 g, 1.3 mmol) and 1-(3-chloropropoxy)-4-fluorobenzene (2.0 g, 1.1 mmol) in dry DMF (10 mL) was heated on an oil bath (80 °C) for 18 h. Once

cool, CHCl₃ (25 mL), and then H₂O (50 mL), was added to the reaction mixture, and the layers were separated. The aqueous portion was washed with CHCl₃ (3 × 10 mL), and the combined CHCl₃ portions were washed with NaOH (0.4 N, 10 mL), dried (Na₂SO₄), and evaporated to dryness to give 3.4 g of a fluffy white solid (mp 105–109 °C). A mixture of this phthalimide (1.9 g, 6.3 mmol) and 85% hydrazine hydrate (2.4 g) in absolute EtOH (100 mL) was heated at reflux for 3 h. After the reaction mixture had cooled to room temperature, the precipitate was removed by filtration and washed with CHCl₃ (20 mL). The combined filtrate and washing was evaporated to dryness in vacuo and the resulting crude product was taken up in CHCl₃ (50 mL), washed with H₂O (3 × 25 mL), dried (Na₂SO₄), and the solvent was removed under reduced pressure to afford 1.0 g (93%) of the free base as a clear oil. The hydrochloride salt was prepared and recrystallized from an absolute EtOH/anhydrous Et₂O mixture to afford the product as white crystalline flakes; mp 168–171 °C (see Table I).

Compound 3 was prepared in a similar manner from 4-chloro-1-(4-fluorophenyl)butan-1-ol (27) (see Table I).

1-[3-(4-Fluorophenoxy)propyl]-N-phenylisonipecotamide (16). **Method B.** A mixture of N-phenylisonipecotamide (33) (102 mg, 0.5 mmol), 28 (74 mg, 0.5 mmol), anhydrous K₂CO₃ (70 mg, 0.5 mmol), and a few crystals of NaI in dioxane (10 mL) was heated at reflux overnight (16 h). The hot reaction mixture was filtered and the solvent was evaporated under reduced pressure; the residue was chromatographed on a silica gel column (column size: 1 × 18 cm; 6 g silica gel, 60 mesh) using a CHCl₃/MeOH (9:1) mixture to give an oily product. The oil was taken up in Et₂O (20 mL) and treated with a saturated solution of oxalic acid in anhydrous Et₂O to afford the hydrogen oxalate salt; mp 168–170 °C (see Table I).

Compounds 6, 8, 9, 10, 12, 13 were all prepared by a similar alkylation procedure (see Table I).

4h(N,N-Dimethylamino)-1-(4-fluorophenyl)-1-butanone Hydrochloride (7). **Method C.** 2-(4-Fluorophenyl)-2-(3-phthalimidopropyl)-1,3-dioxolane (2.8 g; mp 149–150 °C) was prepared by heating a solution of 2-(3-chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane (2.1 g, 8.7 mmol) and potassium phthalimide (2 g) in dry DMF (8 mL) at 80 °C under N₂ for 18 h. The resultant crude product was subjected to hydrazinolysis to afford 1.1 g (90%) of the ketal-protected keto amine 34 (clear oil; bp 48 °C, 0.04 mmHg) as described for compound 5. [³H NMR (CDCl₃) δ 1.5 (m, 2H, CH₂), 1.9 (m, 2H, CH₂), 2.6 (t, 2H, CH₂), 3.6–4.1 (m, 4H, CH₂), 6.9–7.1 (m, 2H, ArH), 7.2–7.5 (m, 2H, ArH); IR (neat) 3400 (NH₂) cm⁻¹.] Formaldehyde solution (37%; 0.5 mL, 6.5 mmol) was slowly added to a cooled solution of the dioxolane (0.5 g, 2.2 mmol) in formic acid (0.25 mL) and the mixture was heated at 80 °C for 24 h. The reaction mixture was acidified by the addition of 6 N HCl (10 mL) and was subsequently washed with Et₂O (3 × 5 mL). The aqueous solution was basified by addition of 50% NaOH (10 mL) and extracted with Et₂O (3 × 10 mL). The combined Et₂O fractions were dried (MgSO₄), and the solvent was removed under reduced pressure to give 0.28 g (61%) of the free base as an oil. Treatment of the free base with an ethereal solution of HCl afforded 7 as off-white crystals after recrystallization from a mixture of EtOAc and absolute EtOH; mp 133–135 °C (see Table I).

1-[3-(4-Fluorophenoxy)propyl]-4-(N-methyl-N-phenylamino)piperidine Hydrogen Oxalate (14). **Method D.** A mixture of 13 (free base, 50 mg, 0.12 mmol) and formaldehyde solution (37%; 3 mL) in 95% EtOH (10 mL) was hydrogenated overnight (ca. 16 h) in the presence of 10% Pd/C (10 mg). The catalyst was removed by filtration and the solvent was evaporated under reduced pressure to afford a crude product. The oil was chromatographed on a silica gel column (column size: 1 × 10 cm; 3 g of silica gel) using a CHCl₃/MeOH (9:1) mixture as eluent. Treatment of the homogeneous oily product with a saturated solution of oxalic acid in anhydrous Et₂O gave 0.02 g (38%) of 14 after recrystallization from an absolute EtOH/anhydrous Et₂O mixture; mp 145–147 °C (see Table I).

4-Benzamido-1-[3-(4-fluorophenoxy)propyl]piperidine Maleate (15) **Method E.** A solution of 31 (260 mg, 0.5 mmol), ammonium acetate (3.8 g, 4.9 mmol), and NaCNBH₃ (25 mg, 0.45 mmol) in MeOH (10 mL) was allowed to stir at room temperature for 48 h. The pH was adjusted to 2 by the addition of concentrated hydrochloric acid and the MeOH was removed

by evaporation under reduced pressure. Water (10 mL) was added and the solution was extracted with Et₂O (3 × 10 mL). The aqueous portion was adjusted to pH 10 by addition of solid KOH and the solution was again extracted with Et₂O (3 × 10 mL); the Et₂O extract was washed with H₂O (3 × 10 mL) and dried (MgSO₄), and the solvent was removed by evaporation under reduced pressure to afford 150 mg of the crude amine **32**, which was used without further purification or characterization. Benzoyl chloride (84 mg, 0.6 mmol) in CHCl₃ (10 mL) was added in a dropwise manner to a stirred solution of **32** (150 mg, 0.6 mmol) and NEt₃ (60 mg, 0.6 mmol) in CHCl₃ (10 mL). After the addition was complete, stirring was allowed to continue for an additional 6 h. The solvent was evaporated under reduced pressure, the solid residue was dissolved in Et₂O (20 mL), the solution was filtered, and the filtrate was washed with 5% NaOH (5, 3, and 2 mL) and then with like portions of H₂O. The Et₂O solution was dried (Na₂SO₄) and evaporated to dryness. The homogeneous solid residue (mp 145–147 °C) was treated with maleic acid in Et₂O to afford 150 mg (53%) of **15** after recrystallization from an absolute EtOH/anhydrous Et₂O mixture: mp 195–197 °C; ¹H NMR (free base; DMSO-*d*₆): δ 1.7 (m, 6H, 3CH₂), 2.9 (m, 4H, 2CH₂), 3.4 (m, 2H, CH₂), 3.8 (m, 3H, CH₂ and CH), 6.0 (s, 2H, —CH=CH—), 6.8–7.8 (m, 9H, Ar-H), 8.3 (d, 1H, NH) (see Table I).

8-[4-(4-Fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Hydrochloride (18) Method F. A mixture of 4-(4-fluorophenyl)butanol *p*-tosylate (0.5 g, 1.4 mmol) and 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (0.3 g, 1.2 mmol) in toluene (10 mL) was allowed to stir overnight (ca. 16 h) at 80 °C. When the reaction mixture was cool, the solvent was evaporated under reduced pressure and the residue was triturated with Et₂O (50 mL). Insoluble material was removed by filtration and the filtrate was evaporated to dryness to give **18** as the free base. An Et₂O solution of the amine was treated with HCl gas to give 0.08 g (17%) of **18** as a white solid material; mp 204–207 °C (see Table I).

Compounds 19–26 were prepared in a similar manner (see Table I).

N-Phenylisonipecotamide (33). A solution of isonipecotic acid (0.52 g, 4 mmol) in trifluoroacetic anhydride (2 mL) was heated at reflux for 2 h and then allowed to stir at room temperature overnight. Solvent was evaporated under reduced pressure and the residue was triturated with Et₂O to give 0.6 g of *N*-(trifluoroacetyl)isonipecotic acid after recrystallization from 2-PrOH/hexanes; mp 119–120 °C (lit.²¹ mp 117 °C). Thionyl chloride (4 mL) was added to 0.5 g of the *N*-protected isonipecotic acid and the mixture was heated at reflux for 2 h. Excess SOCl₂ was removed by evaporation and a solution of the residue in CHCl₃ (10 mL) was treated with a solution of aniline (0.23 g, 2.5 mmol) in CHCl₃ (5 mL). After stirring of the reaction mixture at room temperature for 2 h, solvent was removed by evaporation under reduced pressure and the residue was dissolved in Et₂O (20 mL). The ethereal solution was washed with 10% HCl (10 and 5 mL), 10% NaOH (10 and 5 mL), and H₂O (10 and 5 mL), dried (MgSO₄), and evaporated to dryness. Recrystallization of the crude product from MeOH gave 0.7 g of the amide; mp 144–146 °C. Removal of the trifluoroacetyl protecting group was achieved by allowing the amide (0.5 g) to stir in 10% NaOH (10 mL) at room temperature for 2 h. The product was extracted from the aqueous solution with Et₂O (10, 5, 2 mL) and the combined Et₂O solution was washed with H₂O (10, 5, 2 mL), dried (MgSO₄), and evaporated to dryness. Recrystallization from an acetone/hexanes mixture gave 200 mg of **33**; mp 138–139 °C (lit.²² mp 137–138 °C).

1-[3-(4-Fluorophenoxy)propyl]piperidone (31). A mixture of **28** (1.9 g, 0.1 mol) and 1,4-dioxo-8-azaspiro[4.5]decane (**29**) (1.3 g, 0.1 mol), K₂CO₃ (1.4 g), and a few crystals of KI in dioxane (40 mL) was heated at reflux for 6 h. Upon cooling, the reaction mixture was filtered and the solvent was evaporated under reduced pressure. The residue in Et₂O (30 mL) was washed with H₂O (3 × 10 mL) and dried (MgSO₄), and a saturated solution of oxalic acid in anhydrous Et₂O was added to afford 1.6 g (42%) of **30** as the salt; mp 166–168 °C. Treatment of an HOAc (30%; 10 mL) solution of **30** with a few drops of concentrated HCl and gentle warming overnight removed the protecting group. The reaction mixture was neutralized by the dropwise addition of

10% NaOH; the resultant oil was extracted with Et₂O (3 × 10 mL) and the Et₂O solution was washed with H₂O (3 × 10 mL) and dried (MgSO₄). (A sample of the oxalate salt was prepared and recrystallized from absolute EtOH/anhydrous Et₂O; mp 186–188 °C.) ¹H NMR (DMSO-*d*₆) δ 2.1 (m, 2H, CH₂), 2.7 (t, 4H, 2CH₂), 3.2 (m, 6H, 3CH₂), 4.2 (t, 2H, CH₂), 7.2 (m, 4H, Ar-H); IR (KBr) 1735 cm⁻¹. Compound **31** was used without further characterization for the preparation of **15**.

Radioligand Binding. Radioligand binding assays were performed as previously reported in detail.^{23,24} Briefly, frontal cortical regions of male Sprague–Dawley rats (200–250 g, Charles River) were dissected on ice and homogenized (1:10 w/v) in ice-cold buffer solution (50 mM Tris HCl, 0.5 mM EDTA, and 10 mM MgCl₂ at pH 7.4) and centrifuged at 3000g for 15 min. The pellet was resuspended in buffer (1:30 w/v), incubated at 37 °C for 15 min and then centrifuged twice more at 3000g for 10 min (with resuspension between centrifugations). The final pellet was resuspended in buffer which also included 0.1% ascorbate and 10⁻⁵ M pargyline.

Assays were performed in triplicate in a 2.0-mL volume containing 5-mg, wet weight of tissue and 0.4 nM [³H]ketanserin (76 Ci/mmol; New England Nuclear) for 5-HT₂ receptor assays, and 10 mg wet weight of tissue and 1 nM [³H]mesulergine (75.8 Ci/mmol; Amersham) for 5-HT_{1C} receptor assays. Cinanserin (1.0 μM) was used to define nonspecific binding in the 5-HT₂ assay. In the 5-HT_{1C} assays, mianserin (1.0 μM) was used to define nonspecific binding, and 100 nM spiperone was added to all tubes to block the binding of the tritiated radioligand to 5-HT₂ receptors. The 5-HT_{1A} assay²⁴ utilized 0.1 nM [³H]-8-OH-DPAT [8-hydroxy-2-(*N,N*-di-*n*-propylamino)tetralin] (157 Ci/mmol; New England Nuclear) and 4 mg wet weight of rat hippocampal tissue; 8-OH-DPAT (1 μM) was used to determine nonspecific binding. Tubes were incubated for 15 min at 37 °C, filtered on Schleicher and Schuell (Keene, NH) glass-fiber filters (presoaked in polyethyleneimine), and washed with 10 mL of ice-cold buffer. The filters were counted at an efficiency of 50%.

Saturation and competition experiments were analyzed using an updated version of the program EBDA²⁵ to obtain equilibrium dissociation constants (*K*_D), *B*_{max}, Hill coefficients, and IC₅₀ values. *K*_i values for competition experiments were obtained using the equation $K_i = IC_{50}/(1 + (D^*/K_D^*))$ where IC₅₀ is the experimentally observed concentration of competing drug that inhibits 50% of specific binding, *K*_D^{*} is the equilibrium dissociation constant determined in saturation studies, and *D*^{*} is the concentration of radioactive ligand used in the competition assays.²⁶ Serotonin hydrogen oxalate and spiperone were obtained from Sigma (St. Louis, MO).

Drug-Discrimination Studies. We have previously trained rats to discriminate DOM from saline vehicle;²⁷ an identical training procedure was used in the present investigation. The subjects were five male Sprague–Dawley rats weighing 250–300 g at the start of the study. The animals were first trained to lever-press for a sweetened milk reward using standard two-lever operant chambers (Coulbourn Instruments Model E10-10) housed within sound- and light-attenuating outer chambers. Once lever-pressing behavior was acquired, the animals were trained to discriminate 1.0 mg/kg of DOM from 1.0 mL/kg of 0.9% saline. Briefly, rats were trained to respond on a variable-interval 15-s (VI 15-s) schedule of reinforcement. Once rates of responding stabilized, the animals received an injection of DOM or saline 15 min prior to each session. DOM or saline was administered on a double-alternation schedule (i.e., 2 days DOM, 2 days saline) and training sessions were of 15 min duration. On every fifth day, learning was assessed during an initial 2.5-min nonreinforced (extinction) period followed by a 12.5-min training session. Data collected during the extinction period included percent drug-appropriate lever responding (i.e., the number of responses on the drug designated lever + total number of responses, expressed as a percent) and total responses made during the entire 2.5-min extinction session (expressed as responses/min).

Once the rats consistently made >80% of their responses on the drug-appropriate lever after administration of DOM, and <20% of their responses on the same lever after injection of saline, stimulus antagonism studies were begun. During these investigations, test sessions were interposed among the training sessions; however, after the 2.5-min extinction period, the animals

were returned to their home cages. During antagonism studies the rats were injected with doses of 26, and then, after 45 min, with 1.0 mg/kg of DOM. Fifteen minutes later, the animals were tested under extinction conditions. Stimulus antagonism was said to have occurred when the animals made $\leq 20\%$ of their responses on the drug-appropriate lever when administered drug in combination with DOM. ED₅₀ (effective inhibition dose 50%) values were determined by the method of Finney.²⁸

1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane hydrochloride (DOM) was obtained from NIDA. All solutions were prepared fresh daily in sterile 0.9% saline and administered via the intraperitoneal route in a 1 mL/kg injection volume.

Acknowledgment. This work was supported in part by PHS Grant DA-01642. We also thank Rodney Higgs for his technical assistance with the drug discrimination studies.

References

- Glennon, R. A.; Westkaemper, R. B.; Bartyzel, P. Medicinal chemistry of serotonergic agents. In *Serotonin Receptor Subtypes*; Peroutka, S. J., Ed.; Wiley-Liss: New York, 1991; pp 19-64.
- Glennon, R. A. Discriminative stimulus properties of hallucinogens and related designer drugs. In *Drug Discrimination: Applications to Drug Abuse Research*; Glennon, R. A., Jarbe, T., Frankenheim, J., Eds.; National Institute on Drug Abuse Research Monograph 116; DHHS Pub. No. (ADM)92-1878; U.S. Govt. Printing Office: Washington, D.C., 1991; pp 25-44.
- Pazos, A.; Hoyer, D. and Palacios, J. M. Binding of serotonergic ligands to the porcine choroid plexus. Characterization of a new type of 5-HT recognition site. *Eur. J. Pharmacol.* 1984, 106, 539-546.
- Weinsbank, R. L.; Adham, N.; Zgombick, J.; Bard, J.; Branchek, T. and Hartig, P. R. Molecular analysis of serotonin receptor subtypes. In *Serotonin Receptor Subtypes: Pharmacological Significance and Clinical Implications*; Langer, S. Z., Brunello, N., Racagni, G., Mendlewicz, J., Eds.; Karger: Basel, 1992; pp 1-12.
- Glennon, R. A.; Raghupathi, R.; Bartyzel, P.; Teitler, M.; Leonhardt, S. Binding of phenylalkylamines at 5-HT_{1C} and 5-HT₂ serotonin receptors: Evidence for a lack of selectivity. *J. Med. Chem.* 1992, 35, 734-740.
- Herndon, J. L.; Ismael, A. M.; Ingher, S. P.; Teitler, M.; Glennon, R. A. Ketanserin analogues: Structure-affinity relationships for 5-HT₂ and 5-HT_{1C} serotonin receptor binding. *J. Med. Chem.* 1992, 35, 4903-4910.
- Glennon, R. A. Do hallucinogens act as 5-HT₂ agonists or antagonists? *Neuropsychopharmacology* 1990, 56, 509-517.
- Glennon, R. A.; Dukat, M. Serotonin receptors and their ligands: A lack of selective agents. *Pharmacol. Biochem. Behav.* 1991, 40, 1009-1017.
- Cheng, S.; Piantadosi, C.; Irvin, J. L. Synthesis and cytotoxicity of 4-aminobutyrophenone hydrochlorides and their substituted pyrimidinylhydrazones. *J. Med. Chem.* 1966, 9, 945-949.
- Grogan, C. H.; Geschickter, C. F.; Freed, M. E. Rice, L. H. Spiranes. VII. Neuroleptics derived from azaspiranes. *J. Med. Chem.* 1965, 8, 62-73.
- Archibald, J. L.; Cavalla, J. F. Antiinflammatory 4-acylaminopiperidines. German Patent 2,144,080, 1970; *Chem. Abstr.* 1972, 77, 343,552.
- Duncan, R. L.; Helsley, G. C.; Welstead, W. J.; DeVanza, J. P.; Funderburk, W. H.; Lunsford, C. A. Arylpiperidines and pyrrolidines. A new class of potent central nervous system depressants. *J. Med. Chem.* 1979, 13, 1-6.
- Janssen, P. A. J. 1-Oxo-2,4,8-triazaspiro[4.5]decanes. U.S. Patent 3,155,670, 1964; *Chem. Abstr.* 1964, 60, 15,882.
- Janssen, P. A. J. 2,4,8-Triazaspirodecan-2-ones. U.S. Patent 3,238,216, 1966; *Chem. Abstr.* 1966, 65, 8,924.
- Glennon, R. A.; Dukat, M. 5-HT receptor ligands—Update 1992, *Current Drugs—Serotonin* 1992, 1, 1-45.
- El-Bermawy, M.; Raghupathi, R.; Ingher, S. P.; Teitler, M.; Maayani, S.; Glennon, R. A. 4-[4-(1-Noradamantanecarbozamido)butyl]-1-(2-methoxyphenyl)piperazine: A high-affinity 5-HT_{1A}-selective agent. *Med. Chem. Res.* 1992, 2, 88-95.
- Recent drug discrimination studies conducted with lisuride (a 5-HT_{1C} antagonist, but a 5-HT₂ partial agonist)¹⁸ using rats trained to discriminate DOM from vehicle also lead to the same conclusion that the DOM stimulus is primarily 5-HT₂, and not 5-HT_{1C}, mediated.¹⁹
- Sanders-Bush, E. Presented at the NIDA Technical Review on Hallucinogenic Agents, Bethesda, MD; July 1992. NIDA Monograph in preparation.
- Glennon, R. A. Presented at the NIDA Technical Review on Hallucinogenic Agents, Bethesda, MD; July 1992. NIDA Monograph in preparation.
- Heng, S.; Piantadosi, C.; Irvin, J. L. Structure and synthesis of 2-(4-substituted phenyl)- Δ^1 -pyrrolines from 4-phthalimidobutyryl chloride via Friedel-Crafts acylation. *J. Pharm. Sci.* 1968, 57, 1910-1916.
- Hibert, M. F.; Hoffmann, R.; Miller, R. A.; Carr, A. A. Conformation activity relationship study of 5-HT₃ receptor antagonists and a definitive model for this receptor site. *J. Med. Chem.* 1990, 33, 1594.
- Lunn, G.; Sansone, E. B. Facile reduction of pyridines with nickel-aluminum alloy. *J. Org. Chem.* 1986, 51, 513-517.
- Teitler, M.; Lyon, R. A.; Davis, K. H.; Glennon, R. A. Selectivity of serotonergic drugs for multiple brain serotonin receptors. *Biochem. Pharmacol.* 1987, 36, 3265-3271.
- Glennon, R. A.; Naiman, N. A.; Lyon, R. A.; Titeler, M. Arylpiperazine derivatives as high-affinity 5-HT_{1A} serotonin ligands. *J. Med. Chem.* 1988, 31, 1968-1971.
- MacPherson, G. A. A personal computer-based approach to the analysis of radioligand binding experiments. *Comput. Programs Biomed.* 1983, 17, 107-114.
- Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50% inhibition (I₅₀) of an enzymatic reaction. *Biochem. Pharmacol.* 1973, 22, 3099-3108.
- Glennon, R. A.; Hauck, A. E. Mechanistic studies on DOM as a discriminative stimulus. *Pharmacol. Biochem. Behav.* 1985, 23, 937-941.
- Finney, D. J. *Probit Analysis*; Cambridge University Press: London, 1952.